entertainment -WSS

entertainment

author：comprehensive 2025-09-28 01:39:55 - browse：81491

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Latigo launches with $135 million for Vertex

WSS

Surgery pushed Ben Carson to fame

Having children helps parents live longer, especially after age 80

Congress must protect the remaining independent doctors

AMAs digital advisors table RPM coding reform proposal, again

Surgery pushed Ben Carson to fame

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

explore

entertainment

knowledge

Virginia high school admissions case could be legal follow

Why Eli Lilly’s earnings didn’t quite live up to the hype

Activists slam private health insurers over coverage restrictions

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Activists slam private health insurers over coverage restrictions

Tome Biosciences co

ChatGPT in medicine: STAT answers readers' burning questions

Why don't Americans have at

Alkermes shareholders re

AMAs digital advisors table RPM coding reform proposal, again

entertainment

What’s missing from the debate over nursing home staff minimums

Artificial intelligence use in health care faces greater scrutiny in 2024

Long Covid research funding gets a major boost from NIH

Long Covid research funding gets a major boost from NIH

Artificial intelligence use in health care faces greater scrutiny in 2024

Artificial intelligence use in health care faces greater scrutiny in 2024

focus

focus

leisure time

hotspot